The Patent Finder
SB

Stealth Biotherapeutics Inc.

First filing 2010
OverviewNotableFeesChangesFamiliesPatent listSources & methods

72 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Aug 2030
Next term end
36
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 21, 2026
    The maintenance fee for Peptide Therapeutics and Methods for Using Same (US 10,293,020) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
  • 2 fees due Dec 13 to 18, 2026 · next Dec 13
  • 3 fees due Apr 3 to 24, 2027 · next Apr 3
  • 1 fee due Jul 7, 2027
    The maintenance fee for Methods for the Regulation of Matrix Metalloproteinase Expression (US 10,525,098) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 2 fees due Sep 3 to 19, 2027 · next Sep 3
  • 3 fees due Oct 2 to 28, 2027 · next Oct 2
  • 1 fee due Nov 12, 2027
    The maintenance fee for Methods and Compositions for the Treatment of Neuropathy and Hyperalgesia (US 10,646,539) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 36 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,470,784Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · High confidence
In forceHigh confidence
US 9,023,807Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · Medium confidence
In forceMedium confidence
US 9,549,963Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · Medium confidence
In forceMedium confidence
US 10,188,692Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · Medium confidence
In forceMedium confidence
US 11,612,633Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · High confidence
In forceHigh confidence
US 11,944,662Methods and Compositions for Preventing or Treating Ophthalmic Conditions
In force
 · Medium confidence
In forceMedium confidence
US 8,697,657Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides
In force
 · High confidence
In forceHigh confidence
US 9,561,258Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides
In force
 · High confidence
In forceHigh confidence
US 10,702,577Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides
In force
 · Medium confidence
In forceMedium confidence
US 9,345,738Methods for the Prevention or Treatment of No-Reflow Following Ischemia/Reperfusion Injury
In force
 · High confidence
In forceHigh confidence
10 of 72 patents shown.
Pro members see all 72.
Pro members: see all 72 patents
Also on record, not counted in the 72: 1 patent in force now held by others · 47 applications pending · 59 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited